12-Jan-2026 6:05 AM CST - Business Wire CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025. Preliminary Fourth Quarter 2025 Financial Results Revenue of approximately $108 million, an increase of 25% ye
10-Nov-2025 7:00 AM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences: Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT. Piper Sandler Hea
4-Nov-2025 3:05 PM CST - Business Wire CareDx Announces Third Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $100.1 million, an increase of 21% year-over-year Testing services revenue of
21-Oct-2025 7:00 AM CST - Business Wire CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast
21-Aug-2025 3:01 PM CST - Business Wire CareDx to Participate in Wells Fargo Healthcare Conference CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, Massachusetts, on September 5, 2025, at 8:00 AM ET. A live and archived webcast of the pres
6-Aug-2025 3:01 PM CST - Business Wire CareDx Announces Second Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass
23-Jul-2025 6:05 AM CST - Business Wire CareDx to Report Second Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim
13-May-2025 3:01 PM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health
30-Apr-2025 3:05 PM CST - Business Wire CareDx Reports First Quarter 2025 Results CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted
12-Jan-2026 6:05 AM CST - Business Wire CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025. Preliminary Fourth Quarter 2025 Financial Results Revenue of approximately $108 million, an increase of 25% ye
10-Nov-2025 7:00 AM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences: Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT. Piper Sandler Hea
4-Nov-2025 3:05 PM CST - Business Wire CareDx Announces Third Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $100.1 million, an increase of 21% year-over-year Testing services revenue of
21-Oct-2025 7:00 AM CST - Business Wire CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast
21-Aug-2025 3:01 PM CST - Business Wire CareDx to Participate in Wells Fargo Healthcare Conference CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, Massachusetts, on September 5, 2025, at 8:00 AM ET. A live and archived webcast of the pres
6-Aug-2025 3:01 PM CST - Business Wire CareDx Announces Second Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass
23-Jul-2025 6:05 AM CST - Business Wire CareDx to Report Second Quarter 2025 Financial Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim
13-May-2025 3:01 PM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health
30-Apr-2025 3:05 PM CST - Business Wire CareDx Reports First Quarter 2025 Results CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted
